Applications of Boc-O-(2-Bromo-Cbz)-L-Tyrosine in Industrial Manufacturing

Boc-O-(2-Bromo-Cbz)-L-Tyrosine serves as a specialized building block within several critical segments of pharmaceutical, peptide, and biotechnology manufacturing. As an original manufacturer, we provide this protected amino acid derivative for integration into finely controlled processes, where quality consistency and regulatory alignment are essential. The following application scenarios reflect established downstream uses supported by strict compliance protocols.

1. Peptide Synthesis for Oncology Drug Development

This compound plays a strategic role in solid-phase peptide synthesis (SPPS) workflows for constructing targeted therapeutic peptides in oncology pipelines. Its dual protection groups facilitate highly selective deprotection steps, contributing to the assembly of peptide chains with minimal racemization and side reactions. Downstream process engineers rely on precisely controlled deblocking and coupling conditions, often under anhydrous and inert atmospheres, to ensure the fidelity of peptide drug intermediates and final APIs designed for anticancer regimens.

Industry compliance standards

• GMP for API (ICH Q7)
• USP <797> for sterile compounding (when relevant)
• European Pharmacopeia Monograph 2034 for peptide substances
• FDA 21 CFR Part 211 for finished pharmaceuticals

Typical usage ratio

• 0.9–1.2 equivalents per coupling step
• Adjusted based on specific peptide sequence length and target purity yield

Downstream process integration

• Feeds into initial chain assembly on resin during automated SPPS cycles
• Participates in deprotection after N-terminal elongation
• Removed in controlled acidolysis prior to final cleavage

Final product types

• Synthetic peptide drug APIs (oncology peptides)
• Peptide-based conjugates (antibody-drug conjugates)
• Peptidomimetic cancer therapeutics

2. Protected Amino Acid Supply for Custom Peptide Manufacturing

Custom peptide production firms order this raw material for their catalog and bespoke offerings, where sequence complexity and high-throughput synthesis require reliable protected tyrosine derivatives. Its bromo-carbobenzyloxy group provides orthogonal protection, conferring selectivity in multi-step peptide chain assembly where functionalization or post-synthetic modification at the tyrosine side chain is necessary. Quality control labs routinely monitor batch purity and identity via HPLC and NMR before dispensing to downstream coupling stations.

Industry compliance standards

• ISO 9001:2015 certified quality management
• Chemical Inventory Control per REACH (EC No. 1907/2006)
• GMP for Starting Materials (guidance by EMA/Q7)
• Certificate of Analysis conforming to in-house monograph

Typical usage ratio

• 1.0–1.1 molar equivalents per protected residue insertion
• Fine-tuned for scale; small batch vs. 100+ liter reactors

Downstream process integration

• Solid- or liquid-phase synthesis reactors
• Weighing and dissolution in DMF/DCM mixture for manual or automated dosing
• Protecting group manipulation in selective deprotection reactors

Final product types

• Custom research-grade peptides
• Diagnostic peptide standards
• Affinity tags for protein purification

3. Pharmaceutical Intermediate for Small Molecule Drug Discovery

Research groups within pharmaceutical companies use this compound as an advanced intermediate in the synthesis of small molecule kinase inhibitors and other tyrosine-derived pharmacophores. Its protected structure permits late-stage functional group transformations, safeguarding sensitive moieties until final deprotection. Medicinal chemists leverage its reactivity under Pd-catalyzed coupling and directed ortho-functionalization reactions to access novel molecular scaffolds for lead optimization campaigns.

Industry compliance standards

• GMP for intermediates (as per ICH Q7 and local regulations)
• SHE (Safety, Health & Environment) protocols for hazardous reagents
• Internal R&D quality specifications for NMR, LC-MS, and residual solvent compliance
• REACH pre-registration for investigational compounding

Typical usage ratio

• 0.8–1.3 molar equivalents depending on synthetic scheme and target yield
• Adjusted according to scale-up and reaction optimization data

Downstream process integration

• Batched into early- or mid-stage organic synthesis as a protected tyrosine derivative
• Feeds into Pd-catalyzed cross-coupling or nucleophilic substitution reactions
• Deprotected by TFA or HBr cleavage in final synthetic step

Final product types

• Tyrosine-derived kinase inhibitors
• Small molecule probe compounds for biological target validation
• Drug discovery intermediates

4. Precursor in Protein Bioconjugation Technology

Manufacturers in the field of bioconjugation procure this raw material for the assembly of modified peptides intended for site-specific labeling. The combination of the Boc and 2-Bromo-Cbz groups allows selective modification at the tyrosine residue, providing a platform for subsequent linker or reporter group introduction. Downstream operations perform controlled deprotection and substitution to introduce bio-orthogonal handles necessary for efficient conjugation of peptides to proteins, fluorophores, or nanoparticles, supporting development of advanced diagnostics and targeted therapeutics.

Industry compliance standards

• ISO 13485:2016 for medical device and diagnostic intermediates
• GMP for production of bioconjugation components (as per ICH Q7)
• Analytical QC guidelines for process intermediates (HPLC/UPLC/MS)
• Documentation traceability under electronic batch records (21 CFR Part 11)

Typical usage ratio

• 0.95–1.0 equivalents relative to the reactive group in the bioconjugation sequence
• Ratio adjusted based on linker chemistry or payload size

Downstream process integration

• Introduced during initial peptide assembly as protected tyrosine
• Selective deprotection and bromo substitution post-synthesis
• Feeds directly into coupling with maleimide, azide, or alkyne-containing linker molecules

Final product types

• Conjugated peptide probes for immunoassays
• Protein-fluorophore conjugates
• Nano-biomaterial conjugation intermediates